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essary duplication of effort must be eliminated. However, doing so is difficult due to 
the current culture of data protectionism and a lack of suitable software that enables 
convenient and useful sharing of the intermediate results. ApproAch: Building on 
our previously published reviews of software for systematic review and trial analyt-
ics, the talk identifies the technical and cultural challenges to be met. We propose 
that a web-based solution enabling the global research community to contribute 
their intermediate results in exchange for access to the data contributed by others 
could rapidly gain momentum. Such a system would challenge data protectionism by 
greatly reducing the level of investment required for data acquisition. conclusion: 
A disruptive web-based system enabling a massively collaborative approach to sys-
tematic reviewing can make data protectionism obsolete and eliminate much of the 
effort required for future systematic reviews.
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The UK government plans to introduce value-based pricing (VBP) for medicines in 
England and Wales from January 2014, and one of the key tenets of the scheme is 
to improve patient access to new innovative drugs. This poster aims to explore the 
extent to which VBP is likely to achieve this goal. To meet this objective, an in-depth 
review of available literature (including white papers from key stakeholders and sci-
entific publications) was conducted. Targeted interviews with five leading thought-
leaders in the implementation of VBP were also conducted to support analysis. 
Research identified a number of areas of uncertainty in VBP implementation that 
could detrimentally impact patient access to new drugs. First, the timeline for the 
VBP negotiation process remains unclear. Currently, it takes NICE on average 48 
weeks to issue guidance on a single technology appraisal, which could be extended 
if a technology is not considered cost-effective. Under VBP, manufacturers will still 
be required to negotiate their price with the Department of Health if the calculated 
VBP price by NICE is unfavorable, and the VBP HTA methodology itself could be more 
complex than the current cost-per-QALY approach. Protracted negotiations could 
also delay access in Scotland and Northern Ireland. Equally, manufacturers may 
postpone launch in the UK if they consider VBP a threat in their price corridor in 
other markets. Finally, it is not clear if additional regional or local level negotiations 
will take place, which could further delay access. In conclusion, although there is 
potential for the new adjustable QALY threshold (which remains to be confirmed) 
to foster innovation, the ability of the new VBP process to expedite patient access 
remains uncertain.
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A choice of business for the pharmaceutical industry “Seguro Popular” in Mexico. 
Abstract Mexico has various providers of health services each one determined to 
a sector of the population where we can find the Mexican Social Security Institute 
(IMSS) that is specifically for workers in the private sector employees and their 
families, the Institute for security and services social of the State workers (ISSSTE) 
for workers in the service of the State or public sector and their families starting 
2003 ushered to the Seguro Popular that extends to the population without social 
security or in State of helplessness in these three mentioned health are emerg-
ing as institutions providing health services larger Mexico insomuch that by 2013 
the Seguro Popular has approximately 54 million affiliates number of successful 
membership in less than 10 years in a country where there is little more than 110 
million of people Seguro Popular is placed, on par with the historic and hegemonic 
IMSS, as the largest buyer of drugs, aware of this are his consumption figures that 
since 2008 has been made public, in such data can find that from 2008 to 2012 they 
have bought 1,241,637,748.68 US Dlls only in drugs consumption regularly since the 
Seguro Popular has several portfolios of services where separate regular conditions 
of sufferings of low frequency and high cost and conditions of very low frequency 
and high cost for children under 5 years who in turn have specific budgets.
disease-sPecific studies 
gastrointestinal disorders – clinical outcomes studies
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objectives: Increasing rates of Clostridium Difficile Infection (CDI), a hospital-acquired 
infection, has stimulated a number of financial incentives and government spon-
sored initiatives to quell the spread of the disease. Previous research has shown the 
impact of CDI on hospital length of stay to attempt to quantify the resource impli-
cations. The purpose of this study is to evaluate the impact of CDI on in-hospital 
mortality. Methods: Data were obtained from national hospital episode databases 
in England, The Netherlands, and Spain. Only patients over the age of 50 and those 
diagnosed with diabetes, chronic kidney disease, heart failure, and chronic obstructive 
pulmonary disease (COPD) were included in the analysis. Cases of CDI were stratified 
between hospital-onset and community-onset cases. Only those that were assumed 
to be hospital-onset were included in the analysis. A logistical regression was used to 
predict the relative effect hospital-onset CDI had on in-hospital mortality. A number 
of covariates were controlled for including: age, sex, comorbidities, and length of stay 
but varied between countries depending on the availability of data. results: Patients 
with hospital-onset CDI had an overall higher mortality rate compared to those who 
horizontal differentiation), which is often cited (beside R&D costs) as the second barrier 
to entry to the branded market. Here, we have discussed several examples of Cournot 
model within various ATC4 groups and jurisdictions. We have also critically examined 
preponderance of »me-too« entries, particularly in the light of an R&D investment of 
the branded firms. Historically, »me-too« drugs are more ubiquitous than often real-
ized by regulatory agencies, payers, and also the pharmaceutical industry itself. This 
unfortunately presents an inefficient use of resources as the breakthough innovation 
is nowadays, in the time of austerity measures, a real necessity. The models that would 
give incentives to the industry to invest in R&D for breaktrough therapies are possible 
and would not only contribute to optimization of societal welfare but would also in 
the long run increase an R&D productivity of branded firms.
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This poster seeks to highlight the key challenges and opportunities surrounding patient 
access to innovative cell therapies in the EU5 and US. The findings are based on second-
ary research of commercialised cell therapies as well as primary research with payers 
in EU5 and US. Cell therapies have a unique opportunity to improve patient outcomes 
but face their own set of challenges due to being cell based. As many of these thera-
pies involve manipulation of the patients’ own cells before being reintroduced (e.g., 
ChondroCelect), the associated side effects are likely to be minimal. Other therapies 
(e.g., gene therapy, Glybera) involve the introduction of foreign genetic material but 
provide a potential long-term cure. However, there are some important challenges that 
must be assessed when considering how to commercialise such therapies. In the case of 
therapies where a patient’s cells are manipulated ex vivo, who bears the risk if the patient 
does not receive their individualised treatment? For those therapies that purport to cure 
disease, how much are health care systems willing to pay for them and what evidence 
would be required in order to justify a high price? Moreover, for all therapies, there is the 
uncertainty regarding access pathways: will cell therapies necessarily undergo an HTA 
evaluation to gain access in the EU? What are the criteria that will be used to determine 
whether such a therapy is deemed a product (and, hence, undergo an assessment like 
a regular biopharmaceutical) or a procedure (and likely bypass a national evaluation)? 
In conclusion, cell therapies face uncertainties in market access and funding due to 
unestablished pathways for the spectrum of interventions that fit under the cell therapy 
umbrella. Until frameworks have been put in place, each cell therapy should be assessed 
individually in order to determine likely pathway to patient access.
PHP231
tHe imPact of recent generic drug Price Policies on PHarmaceutical 
innoVation: a tHeoretical rationale and ProPosal of a metHod 
suPPorting innoVation in areas of unmet medical need
Dionne P.A.1, Ali F.1, Grobler M.2
1Pfizer Canada, Kirkland, QC, Canada, 2Pfizer Australia, West Ryde, NSW, Australia
New discoveries are a critical priority for the pharmaceutical industry, for which 
the primary aim should be to address unmet medical needs. However, the use of 
fixed cost-effectiveness (ICER) thresholds for health technology assessment (HTA) 
may tend to decrease incentives to innovate and affect future treatment options. 
This presentation highlights, using a case study, the impact of recent generic drug 
price policies on pharmaceutical innovation in the context of fixed ICER thresh-
olds and proposes a new consideration for the cost-effectiveness analysis (CEA). 
There is a direct causal relationship between HTA and the market price of a drug; 
in jurisdictions where HTA agencies apply fixed ICER thresholds as an important 
reimbursement listing criterion, the incremental cost of a new drug is expected to be 
proportional to its incremental benefit over the comparator. However, the compara-
tor price is subject to market forces or sudden policies and may change markedly 
affecting the cost-effectiveness assessment (e.g. where the comparator patent has 
expired). Since recent generic price regulations (e.g. 18% or 25% of the innovative 
price in Canada) increased the price gap between drugs’ generic and patented ver-
sions, it is harder to achieve a sufficient level of incremental benefits in order to 
offset incremental prices of new treatments. This analysis thus demonstrates that 
with recent changes in generic drug prices in Canada and other jurisdictions, even 
promising drugs will have challenges to show attractive ICERs. Traditional decision-
making process should be adapted to reflect these changes and to promote innova-
tion in therapeutic fields with unmet medical needs. A compromise would be to 
include the comparator’s patented price in the CEA instead of the generic drug in 
certain areas of unmet needs. By identifying the relevant disease areas, decison 
makers and HTA authorities could convey the importance of investing in these 
therapeutic areas to manufacturers.
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bAckground: The scope of systematic reviews and health technology assessments 
is rapidly expanding due to increasing demand for more complex models that account 
for patient, treatment, and trial characteristics, network meta-analyses that include 
more interventions, and the growing number of clinical trials. By the year 2000, the 
effort required to publish a typical systematic review had already reached the thou-
sands of person-hours, which were predominantly spent on data acquisition tasks. 
Innovative solutions are required to prevent the costs of comparative effectiveness 
research from ballooning out of proportion. probleM: Typically only the end product 
of systematic reviewing, a report summarizing the evidence, is made widely avail-
able. However, capturing the intermediate results of literature searching, publication 
screening, and data extraction has the potential to greatly enhance the efficiency of 
future reviews. In the face of the increasing scope of systematic reviews, this unnec-
